台北中医医学杂志

96.04 乳癌患者服用人叁之安全性探讨
乳癌患者服用人叁之安全性探讨
Safety Issues for Those Patients with Breast Cancer who Take Ginseng
陈安履 林舜谷*
台北市立联合医院仁爱区中医科
【摘要】
许多乳癌患者会接受中医治疗,也会服用包含人身的中药方剂。但许多患者与临床医师担心人叁可能会加速乳癌细胞分裂,建议患者避免服用。细胞试验表明人叁会刺激乳癌细胞的雌激素受体,增加DNA 和RNA 的表现,但反而会降低癌细胞的存活率。此外,大规模的病人数据追踪结果显示,正在接受 Tamoxifen 治疗的乳癌患者,若也接受人叁治疗并不会增加子宫内膜癌的风险。而更年期妇女服用人叁,也不会增加罹患乳癌的风险。
【关键词】乳癌、人叁、子宫内膜癌、人叁皂苷、中西药交互作用
 
An-Lu Chen Shun-Ku Lin*
Department of Chinese Medicine, Taipei City Hospital, RenAi Branch. Department of
Health, Taipei City Covernment
【Summary】
Many patients with breast cancer pursue Traditional Chinese medication (e.g., Chinese medicine compounds containing Ginseng). However, some clinical doctors recommend patients to avoid taking Ginseng since it may enhance cytokinesis of cancer cells. In fact, cell tests revealed that Ginseng can enhance the activity of estrogen receptor of breast cancer cells. As a result, the survival rate of cancer cells is greatly reduced. Furthermore, the data base established by retrospective studies showed that Ginseng did not increase the risk of endometrial carcinoma for those patients with breast cancer who took Tamoxifen. In addition, Ginseng does not cause the increased risk of breast cancer in menopausal women.
【Keywords】Breast cancer, Ginseng, endometrial carcinoma, Ginsenoside, Herbal-drug Interactions